Journal of Clinical Oncology

HLA associations with immunotherapy related endocrine toxicity.

Journal of Clinical Oncology

Zoe Quandt, Christian Thorball, Pooja Middha, Douglas Buckner Johnson, Cosmin A Bejan, Lydia Yao, Yaomin Xu, Flavia Hodel, Athina Stravodimou, Esther Shearer-Kang, Geoffrey Liu, Melinda C Aldrich, Adam Jacob Schoenfeld, Elad Ziv, Elizabeth J Phillips, Jacques Fellay, Ewa A Bergmann, G Scott Chandler, Justin M Balko, Ashis Saha

Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.

Journal of Clinical Oncology

Kirkpatrick B Fergus, Pooja Middha, Zoe Quandt, Yiwey Shieh, Amrita B Basu, Rosalyn Sayaman, Paula R Pohlmann, Douglas Yee, Rebecca Arielle Shatsky, Claudine Isaacs, Michael J. Campbell, Gillian L. Hirst, Lamorna Brown Swigart, Laura van 't Veer, Elad Ziv, Laura Esserman

Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.

Journal of Clinical Oncology

Rita Nanda, Ronald Cohen, Zoe Quandt, Amrita B Basu, Christina Yau, Amy Jo Chien, Lajos Pusztai, Hyo S. Han, Erica Michelle Stringer-Reasor, Claudine Isaacs, Dawn L. Hershman, Rebecca Arielle Shatsky, Jane Perlmutter, Douglas Yee, Angela DeMichele, Laura van 't Veer, Nola Hylton, Laura Esserman, Hope S. Rugo

The cognitive load of inpatient consults involving immune-related adverse events.

Journal of Clinical Oncology

Sam Brondfield, Jordyn Silverstein, Kimberly de Dios, Zoe Quandt

Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.

Journal of Clinical Oncology

Saya Jacob, Zoe Quandt, Michelle E. Melisko, Melanie Majure, Amy Jo Chien, Anne Hudson Blaes, Diane Heditsian, Laura Esserman, Hope S. Rugo

Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with alpelisib (ALP).

Journal of Clinical Oncology

Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Faye Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin Kaffenberger, Bernice Y. Kwong, Timothy J. Pluard, Ruta D. Rao, Lee S. Schwartzberg, Michael S. Broder

Immune checkpoint inhibitor–induced diabetes mellitus across NCI trials.

Journal of Clinical Oncology

Zoe E. Quandt, Vanessa Hill, Joe E. Dib, Jason Burian, Sapir Tessler, Abdul Rafeh Naqash, Mark S Anderson, Megan Othus, Elad Sharon

Evaluating survival following severe immune-related adverse events requiring hospitalization.

Journal of Clinical Oncology

Francis Wright, Daniel Myung Kim, Jordyn Silverstein, Michelle Wang, Kimberly de Dios, Arabella Young, Zoe E. Quandt, Sam Brondfield

Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.

Journal of Clinical Oncology

Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Sarah E Umetsu, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong

Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.

Journal of Clinical Oncology

Robin Kate Kelley, Emily Mitchell, Spencer Behr, Jimmy Hwang, Bridget Keenan, Sarah E Umetsu, John Dozier Gordan, Andrew H. Ko, Pelin Cinar, Chloe Evelyn Atreya, Katherine Van Loon, Thomas Weber, Zoe Ngo, Zoe E. Quandt, Chienying Liu, Alan P. Venook, Lawrence Fong

Pages